Non-Hodgkin’s Lymphoma Center Posts New Study for Effective Treatment of B-cell Non-Hodgkin’s Lymphoma

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
This is an important study because the secondary endpoints included progression-free survival. This means that the results are based on actual patient survivability and not just surrogate end points like response rate.

Raleigh, North Carolina (PRWEB) March 25, 2014

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at http://nonhodgkinslymphomas.com/drug-may-offer-new-hope-for-follicular-lymphoma/

Scientists at the Department of Haematology and Oncology at the Nagoya Daini Red Cross Hospital in Japan have concluded that a drug called Zolinza (vorinostat) may improve outcomes for patients fighting indolent B-cell lymphomas like follicular lymphoma and mantle cell lymphoma.

Dr. Michinor Oquora, the lead author of the study, stated that “Vorinostat (Zolinza) offers sustained antitumor activity in patients with relapsed or refractory follicular lymphoma with an acceptable safety profile.”

The Phase II study, published in the British Journal of Haematology tested Zolinza on fifty Non-Hodgkin’s Lymphoma patients (39 with follicular lymphoma) whose disease had come back after treatment. The results were encouraging.

“This is an important study because these results are not just projected numbers from the lab. This research is based on people who survived,” said Alex Strauss, Managing Editor of the Non-Hodgkin’s Lymphoma Center. Follicular lymphoma is a B-cell cancer that accounts for about one fourth of all Non-Hodgkin’s Lymphomas.

To learn more about this study including how Zolinza is thought to work, the specific results of the study, and the most serious complications see: Drug May Offer New Hope for Follicular Lymphoma available now on the Non-Hodgkin’s Lymphoma Center website.

Oqura, M et al, “A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell Non-Hodgkin’s Lymphoma and mantle cell lymphoma”, British Journal of Haematology, March 12, 2014, Epub ahead or print, http://www.ncbi.nlm.nih.gov/pubmed/24617454)

The Non-Hodgkin’s Lymphoma Center is part of the Cancer Monthly organization. The Non-Hodgkin’s Lymphoma Center has been established by Cancer Monthly to provide more comprehensive information on the causes, diagnosis, and treatments for the many different subtypes of Non-Hodgkin’s Lymphoma. For over ten years, Cancer Monthly has been the only centralized source of cancer treatment results. Patients can see the actual survival rate, quality-of-life indicators, and other key data for approximately 1,500 different cancer treatments. Cancer Monthly provides timely and ground-breaking news on the causes, diagnoses and treatments of the most common cancers including Bladder, Brain, Breast, Colon, Kidney (Renal), Liver, Lung (NSCLC), Ovarian, Prostate, and Rectal Cancers, Melanoma, Mesothelioma, and Non-Hodgkin's Lymphoma. Written for patients and their loved ones, Cancer Monthly helps families make more informed treatment decisions.


Contact

Follow us on: Contact's Google Plus